1/16
Looks like no tags are added yet.
Antithrombin trialists' collaboration 2002
75-150 mg/day of ASA helps
with CV event prevention in PAD
What is the point of these trails in regard to ASA?
CLIPS trial 2007
POPADAD trial 2008
JAMA Meta-analysis 2009
JAMA Low ABI population trial 2010
That aspirin helped symtopmatic PAD patients more than asymtomatic PAD patinets.
CLIPS trial 2007
general PAD population (3/4 symptomatic): Significant reduction in major vascular events with low-dose ASA
POPADAD trial 2008
asymptomatic PAD pts: No significant reduction in composite of CV events, CV death,
or CLI-related amputation with low-dose ASA
JAMA Meta-analysis 2009
2/3 symptomatic PAD pts: statistically significant reduction in non-fatal CVA, but no
significant difference in other CV events.
JAMA Low ABI population trial 2010
All asymptomatic PAD pts: No significant reduction in fatal or non-fatal CV events or
mortality.
CAPRIE trial 1996
Clopidogrel vs Aspirin:
Clopidogrel may reduce CV event risk more than aspirin
CHARISMA trial
PAD w/ no recent vascularization pts:
Aspirin vs. Clopidogrel + Aspirin:
Dual therapy little more benefit over ASA alone & helps in regards to MI & hospitalization for ischemia
BUT associated with
increased bleeding
CASPAR Trial
ASA + Clopidogrel following
surgical revascularization vs ASA alone:
ASA + clopidogrel combo significantly reduces composite
of MALE or death in patients with prosthetic below-knee bypass
grafting compared to ASA alone
Observational Study of DAPT following
endovascular revascularization vs ASA alone
Following endovascular revascularization, DAPT was
associated with small survival benefits that were sustained through
five-years of follow-up.
EUCLID Trial
Ticagrelor is not superior to clopidogrel for
CV event reduction in patients with symptomatic PAD
TRACER Study
(Vorapaxer stopped)
TRIAL STOPPED ~6
MONTHS EARLY DUE TO
PRESPECIFIED #
ENDPOINTS BEING
REACHED & ↑ ICH RISK
TRA2P-TIMI 50 Study
VORAPAXAR STOPPED
IN ALL PATIENTS WITH
PRIOR CVA AFTER ~2
YEARS OF FOLLOW-UP
DUE TO TRACER STUDY
ICH RISK
What is a summary for Vorapxer
pts with PAD: vorapaxar may ↓MALE BUT does not ↓MACE & ↑bleeding (signficant)
COMPASS Trial
Symptomatic PAD pts: Rivaroxaban 2.5 mg BID + low-dose ASA = ↓ MACE & MALE and ↓ bleed risk, but was associated w/ ↑major bleeding.
VOYAGER PAD Trial
PAD patients w/ revascularization: Rivaroxaban 2.5 mg BID + low-dose ASA ↓ MACE & MALE in , but may be associated with ↑ major bleeding.
STRIDE Trial
symptomatic PAD + T2DM pts: Semaglutide improved walking distance in patients